|Bid||279.00 x 800|
|Ask||290.66 x 2200|
|Day's Range||289.94 - 295.89|
|52 Week Range||187.16 - 311.88|
|Beta (5Y Monthly)||0.17|
|PE Ratio (TTM)||15.04|
|Earnings Date||Feb 01, 2023 - Feb 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||295.44|
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo. Eisai has also filed for approval of the drug in Japan.
TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of